SCHEMBL896485

SCHEMBL896485

COc1c(Br)cc(N)cc1-c1ccc2cc(NS(C)(=O)=O)ccc2c1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CRBN Q96SW2 1/20 0.48
TP53 P04637 1/20 0.42
KDM1A O60341 1/20 0.39
FYN P06241 1/20 0.39
TGFBR1 P36897 1/20 0.39
ACVR1 Q04771 1/20 0.39
BRPF1 P55201 1/20 0.39
HSP90AA1 P07900 2/20 0.39
HSP90AB1 P08238 2/20 0.39
PLAU P00749 4/20 0.39
JAK2 O60674 2/20 0.36
JAK1 P23458 2/20 0.36
TYK2 P29597 2/20 0.36
JAK3 P52333 2/20 0.36
MET P08581 1/20 0.36
IDO1 P14902 1/20 0.36
TDO2 P48775 1/20 0.36
LMNA P02545 1/20 0.36
GAA P10253 1/20 0.36
MAPK1 P28482 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL482542 0.86 CRBN (0.48) CRBNTP53KDM1ABRPF1PLAU
SCHEMBL897095 0.82 CRBN (0.45) CRBNTP53KDM1APLAULMNA
SCHEMBL482973 0.82 CRBN (0.45) CRBNTP53KDM1AFYNTGFBR1
SCHEMBL482538 0.82 CRBN (0.52) CRBNTP53KDM1AFYNTGFBR1
SCHEMBL482820 0.79 CRBN (0.43) CRBNTP53KDM1AACVR1BRPF1
SCHEMBL482819 0.79 CRBN (0.43) CRBNTP53KDM1AACVR1BRPF1
SCHEMBL1530175 0.77 CRBN (0.77) CRBNTP53BRPF1PLAUJAK2
SCHEMBL2911158 0.76 CRBN (0.52) CRBNTP53BRPF1PLAUJAK2
SCHEMBL482534 0.76 CRBN (0.54) CRBNTP53BRPF1PLAUIDO1
SCHEMBL28563350 0.75 HSD17B1 (0.47) TP53HSP90AA1METLMNAMAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9637478-B2 Antiviral compounds and uses thereof ABBVIE INC. (US) 2017-05-02 US disclosed
EP-2411352-B1 ANTIVIRAL COMPOUNDS AND USES THEREOF ABBVIE INC (US) 2017-01-18 EP disclosed
US-20160368905-A1 ANTIVIRAL COMPOUNDS AND USES THEREOF ABBOTT LABORATORIES 2016-12-22 US disclosed
US-9353091-B2 Antiviral compounds and uses thereof ABBVIE INC. (US) 2016-05-31 US disclosed
US-20150056164-A1 Antiviral Compounds and Uses Thereof ABBVIE INC. (US) 2015-02-26 US disclosed
US-8748443-B2 Antiviral compounds and uses thereof ABBVIE INC. (US) 2014-06-10 US disclosed
US-20120082646-A1 Antiviral Compounds And Uses Thereof ABBOTT LABORATORIES (US) 2012-04-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150056164-A1 Antiviral Compounds and Uses Thereof MAVS, ZC3HAV1, EIF2AK2 CRBN 2389/4885TP53 500/4885KDM1A 4220/4885
US-20160368905-A1 ANTIVIRAL COMPOUNDS AND USES THEREOF MAVS, ZC3HAV1, EIF2AK2 CRBN 2389/4885TP53 500/4885KDM1A 4220/4885
US-20120082646-A1 Antiviral Compounds And Uses Thereof MAVS, ZC3HAV1, EIF2AK2 CRBN 2389/4885TP53 500/4885KDM1A 4220/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.